Effect of Nilvadipine on Memory Impairment and Hippocampal Malondialdehyde in Rats with 4-Vessel Occlusion Ischemia

Abstract

Purpose: Nilvadipine is a dihydropyridine-type calcium channel blocker with emanatingneuroprotective properties in various models of neuronal diseases. This study aimed atinvestigating the prophylactic effect of nilvadipine on memory impairment and hippocampalmalodialdehyde (MDA) levels in global brain ischemia model induced by 4-vessel occlusionischemia (4-VO) in rat.Materials and methods: The 4-VO ischemia was induced in Wistar rats by occluding thevertebral arteries permanently by cauterization. The common carotid arteries were twiceoccluded bilaterally for 10 minute at 60 minute interval. One week after 4-VO the memory wasevaluated measuring the correct and error choices in 8-armed radial maze. The ischemiareperfusion-induced damage was evaluated measuring level of MDA in the hippocampus usingthiobarbituric acid method. The study involved three groups: sham, ischemia-control andischemia nilvadipin. Nilvadipine (3.2 mg/kg/day) was administerd for 7 days prior to 4-VOResults: The 4-VO impaired memory performance by decreasing the correct choices (long termreference memory) and increasing the error choices (short term-working memory) (p

Keywords

• Four-Vessel-Occlusion ischemia, Hippocampus, Memory impairment, Malondialdehyde, Nilvadipine

Dört Damar Oklüzyon Yöntemiyle Beyin İskemisi Oluşturulan Sıçanlarda Nilvadipinin Bellek Bozukluğu Ve Hipokampus Malondialdehit Düzeylerine Etkileri

Abstract

Amaç: Nilvadipin, farklı nöronal hastalık modellerinde nöron koruyucu etki gösterendihidropiridin türevi kalsiyum kanal blokeridir. Bu çalışmada, profilaktik olarak kullanılannilvadipinin, sıçanlarda 4-damar oklüzyonu (4-DO) ile oluşturulan global beyin iskemisimodelinde bellek bozukluğu ve hipokampal malondialdehid (MDA) düzeyine olan etkisininaraştırılması amaçlanmıştır.Gereç ve yöntem: 4-DO iskemi modeli oluşturulmasında, Wistar sıçanların vertebral arterlerikalıcı olarak koterize edilip, ana karotis arterler ise iki taraflı olarak 60 dakika arayla 10 dakikasüreyle 2 defa geçici olarak klemplenmiştir. Bellek işlevi sekiz kollu labirentte doğru seçim veyanlış seçimleri ölçerek değerlendirilmiştir. İskemiden bir hafta sonra tiobarbitürik asityöntemiyle hipokampusta MDA düzeyleri ölçülmüştür. Çalışmamızda sham, iskemi-kontrol veiskemi-nilvadipin olmak üzere üç grup kullanılmıştır. Nilvadipin, iskemi öncesi 7 gün boyuncaintraperitoneal olarak 3,2 mg/kg/gün dozunda verilmiştir.Bulgular: İskemi, doğru seçimleri (uzak-referans bellek) azaltıp yanlış seçimleri (yakın-çalışanbellek) arttırarak (p

Keywords

• Dört-Damar Oklüzyon İskemisi, Hipokampus, Bellek Bozukluğu, Malondialdehid, Nilvadipin

References

1. Roman GC, Sachdev P, Royall DR, Bullock RA, Orgogozo JM, Lopez-Pousa S, Arizaga R, Wallin A. Vascular cognitive disorder: A new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 2004; 226:81–87.
2. Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke 1997; 28: 785–792.
3. Truelsen T, Piechowski-Jozwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol 2006; 13:581–598.
4. Bakar M. Post strok demans (epidemiyoloji ve risk faktörleri). Demans 2003; 1:15–20.
5. Cotran RS, Kumar V, Robbins S. Çeviri editörü: Çevikbaş U: Temel Patoloji. Nobel Tıp Kitabevleri & Yüce Yayınları, İstanbul. Sayfa:3-25, 1994.
6. Van Wijk SJ, Hageman GJ. Poly (ADP-ribose) polymerase-1 mediated ischemia/reperfusion. Free Radic Biol Med 2005; 39:81–90. cell death after
7. Slater TF. Free-radical mechanisms in tissue injury. Biochem J 1984; 222:1–15.
8. Freitas I, Griffini P, Bertone V, et al. In situ detection of reactive oxygen species and nitric oxide production in normal and pathological tissues: improvement by differential interference contrast. Exp Gerontol 2002; 37:591–602.

9. Rosenthal J. Nilvadipine: Profile of a new calcium antagonist. An overview. J Cardiovasc Pharmacol. 1994; 24:92–107.
10. Kobayashi S, Yamaguchi S, Okada K, Suyama N, Bokura K, Murao M, Tsunematsu T. Effect of single oral administration of nilvadipine on cerebral blood flow in chronic cerebral infarction. Angiology 1992; 43:801–809.
11. Ogasawara K, Noda A, Yasuda S, Kobayashi M, Yukawa H, Ogawa A. Effect of calcium antagonist on cerebral blood flow and oxygen metabolism in patients with hypertension and chronic major cerebral artery occlusion: a positron emission tomography study. Nucl Med Commun 2003; 24:71–76.
12. Iwasaki K, Mishima K, Egashira N, et al. Effect of nilvadipine on the cerebral ischemia-induced impairment of spatial memory and hippocampal apoptosis in rats. J Pharmacol Sci 2003; 93:188–196.
13. Kawamura S, Li Y, Shirasawa M, Yasui N, Fukasawa H. Effects of treatment with nilvadipine on cerebral ischemia in rats. Tohoku J Exp Med 1998; 185:239–246.
14. Ishibashi H, Murai Y, Akaike N. Effect of nilvadipine on the voltage-dependent Ca2+ channels in rat hippocampal CA1 pyramidal neurons. Brain Res 1998; 813:121–127.
15. Tsukuda E, Matsuda Y. Effect of benidipine on depolarizing stimulation-induced increase of intracellular calcium concentration in cultured mouse hippocampal neurons. Jpn J Pharmacol 1999; 81:401–403.
16. Himeda T, Kanbara S, Oki C, Kato H, Araki T. Effects of chronic immunohistochemical changes related to aging in the mouse hippocampus. Metab Brain Dis 2005; 20:141–153. against
17. Yamada K, Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 2000; 88:93–113.
18. Pulsinelli WA, Brierley JB, Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 1982; 11:491–498.
19. Smith ML, Bendek G, Dahlgren N, Rosen I, Wieloch T, Siesjo BK Models for studying long-term recovery following forebrain ischemia in the rat. 2. A 2-vessel occlusion model. Acta Neurol Scand 1984; 69:385–401.
20. Duhaime AC, Ross DT. Degeneration of hippocampal CA1 neurons following transient ischemia due to raised intracranial pressure: Evidence for a temperature-dependent excitotoxic process. Brain Res 1990; 512:169–174.
21. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: Association with education. The Rotterdam study. BMJ 1995; 6985:970–973.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95:351–358.
23. Demir S, Özkurt S, Köseoğlu M, Enli Y, Aslan D, Gümüşsu N. Sigara içenlerde plazma lipid peroksidasyonu. Solunum 2001; 3:57–59.
24. Iwasaki K, Chung EH, Egashira N, et al. Non-NMDA mechanism in the inhibition of cellular apoptosis and memory impairment induced by repeated ischemia in rats. Brain Res 2004; 995:131–139.
25. Hatip-Al-Khatib I, Iwasaki K, Chung EH, Egashira N, Mishima K, Fujiwara M. Inhibition of poly (ADP-ribose) polymerase and caspase-3, but not caspase-1, prevents apoptosis and improves spatial memory of rats with twice- repeated cerebral ischemia. Life Sci 2004; 75:1967–1978.
26. Block F. Global ischemia and behavioral deficits. Prog Neurobio. 1999; 58:279–295.
27. Hosseinzadeh H, Sadeghnia HR. Safranal, a constituent of crocus sativus (saffron), attenuated cerebral ischemia induced oxidative damage in rat hippocampus. J Pharm Pharm Sci 2005; 22:394–399.
28. Maia FD, Pitombeira BS, Araujo DT, Cunha GM, Viana GS. l-Deprenyl prevents lipid peroxidation and memory deficits produced by cerebral ischemia in rats. Cell Mol Neurobiol 2004; 24:87–100.
29. Gupta S, Sharma SS. Neuroprotective effects of trolox in global cerebral ischemia in gerbils. Biol Pharm Bull 2006; 29:957–961.
30. Kuwaki T, Satoh H, Ono T, Shibayama F, Yamashita T, Nishimura T. Nilvadipine attenuates ischemic degradation of gerbil brain cytoskeletal proteins. Stroke 1989; 20:78–83.